The randomized phaseII study of SOX and SIR sequential therapy as TS-1 based regimens in Advanced Colorectal Cancer; WSTAR trial - SOAC-1102(WSTAR)

Chiba surgical oncology development association0 个研究点目标入组 130 人开始时间: 2012年4月10日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Serious drug hypersensitivity 2) Pregnant or nursing 3) Active infection 4) Serious coexisting illness diabetes mellitus, uncontrolled or controlled with insulin, uncontrolled hypertension, liver cirrhosis, renal disfaunction, severe pulmonary dysfunction, active infection, history of myocardial infarction 5) Gastrointestinal ulcer or bleeding 6) Sensory neuropathy 7) Hydrothorax or ascites which needs treatment 8) Brain metastasis 9) Gastrointestinal perforation within 6 months 10) Cerebral infarction, myocardial infarction, pulmonary infarction and interstitial pneumonia 11) Operation within 28 dys 12) Congenital bleeding factor 13) Anticoagulation drugs are given to 14) Active synchronous or metachronous malignancy other than carcinoma in situ 15) Past of the hemoptysis 16) Case having the primary lesion genesis with high stenosis 17) The case that peritoneum dissemination or a peritoneum nodule is confirmed with an image 18) Case taking Flucytosine or Atazanavir Sulfate 19) Diarrea 20) Choloplania 21) The continuous case that receive it systematically of the steroid 22) Atopic dermatitis 23) Not suitable for participating in the study for any other reason

发起方

Chiba surgical oncology development association